Latest Information Update: 27 Dec 2016
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cancer
Most Recent Events
- 01 Nov 2016 Phase-I clinical trials in Cancer (Late-stage disease) in China (PO) (NCT02944864)
- 24 Oct 2016 Preclinical trials in Cancer in China (PO) before October 2016